

Business Development

October 2025

**Changing the Treatment
Paradigm for Patients with Iron
Deficiency Anemia**



Disclaimer

These slides have been prepared by Shield Therapeutics plc (the "Company") solely for your information and for use at a presentation for the purpose of providing background information on the Company, its business and the industry in which it operates. For the purposes of this notice, "presentation" means these slides, any oral presentation, any third-party session and any written or oral material discussed or distributed during the presentation meeting. This presentation has not been approved by the United Kingdom Listing Authority under the Prospectus Rules (made under Part VI of the Financial Services and Markets Act 2000, as amended) or otherwise, or by the London Stock Exchange plc. This presentation has not been independently verified and no representation or warranty, express or implied, is made or given by or on behalf of the Company or any of its subsidiaries or subsidiary undertakings, or any of such person's respective directors, officers, partners, employees, agents, affiliates or advisers, as to, and no reliance may be placed for any purpose whatsoever on the information or opinions contained in this presentation or on the completeness, accuracy or fairness thereof.


This presentation does not constitute or form part of, and should not be construed as, any offer, invitation or recommendation to purchase, sell or subscribe for any securities of the Company in any jurisdiction and neither the issue of this presentation nor anything contained herein shall form the basis of or be relied upon in connection with, or act as an inducement to enter into, any investment activity. This presentation does not purport to contain all of the information that may be required to evaluate any investment in the Company or any of its securities and should not be relied upon to form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. This presentation is intended to present background information on the Company, its business and the industry in which it operates and is not intended to provide complete disclosure upon which an investment decision could be made. The merit and suitability of an investment in the Company should be independently evaluated and any person considering such an investment in the Company is advised to obtain independent advice as to the legal, tax, accounting, financial, credit and other related advice prior to making an investment.

No undertaking, representation, warranty or other assurance, express or implied, is or will be made or given by or on behalf of the Company or any of its subsidiary or subsidiary undertakings, or any of such person's respective directors, officers, partners, employees, agents, affiliates or advisers or any other person as to the accuracy or completeness of the information or opinions contained in this presentation and no responsibility or liability is accepted by any such person for any such information or opinions or for any errors, omissions or misstatements, negligent or otherwise, nor for any other communication written or otherwise. All information in this presentation is subject to verification, correction, completion and change without notice. None of the Company or any of its subsidiary or subsidiary undertakings, or any of such person's respective directors, officers, partners, employees, agents, affiliates or advisers, undertakes any obligation to amend, correct or update this presentation or to provide the recipient with access to any additional information that may arise in connection with it.

The statements contained in this presentation may include "forward-looking statements" that express expectations as to future events or results. Forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "seeks" or "should" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These statements are based on current expectations and involve risk and uncertainty because they relate to events and depend upon circumstances that may or may not occur in the future. There are a number of factors which could cause actual results or developments to differ materially from those expressed or implied by such forward-looking statements. Any of the assumptions underlying forward-looking statements could prove inaccurate or incorrect and therefore any results contemplated in forward-looking statements may not actually be achieved. Nothing contained in this presentation should be construed as a profit forecast or profit estimate. Investors and any other recipients of such communications are cautioned not to place reliance on any forward-looking statements. The Company undertakes no obligation to update or revise (publicly or otherwise) any forward-looking statement, whether as a result of new information, future events or other circumstances.

To the extent available, the data contained in this presentation has come from official or third-party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the data contained in this presentation come from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the data contained in this presentation. This presentation should not be copied or distributed by recipients and, in particular, should not be distributed by any means, including electronic transmission, to persons with addresses in the United States of America, Canada, Australia, South Africa or Japan, their possessions or territories or to any citizens thereof, or to any corporation, partnership or such entity created or organised under the laws thereof, or any other jurisdiction, where such distribution is unlawful. Any such distribution contrary to the above could result in a violation of the laws of such jurisdictions.

This presentation is confidential and is being supplied to you solely for your information and may not be reproduced, re-distributed or passed on, directly or indirectly, to any other person or published in whole or in part for any purpose. By attending the meeting where this presentation is made or by accepting a copy of this presentation, you agree to be bound by the limitations and restrictions set out above.



ACCRUFER[®]
(ferric maltol) *30 mg capsules*

#1 branded prescription oral iron
in the US ID/IDA* market

Source: IQVIA Xponent PlanTrak

*ID/IDA: Iron Deficiency with & without Anemia

Shield is actively seeking partners to in license products that can leverage its US infrastructure and expand its portfolio

- Shield Therapeutics plc (LSE: STX) a **commercial-stage** pharmaceutical company
- Experienced Executive Team** with extensive US commercialization expertise
- Lead product **ACCRUFER®** is the **#1 branded prescription** oral iron in the US ID/IDA market with a ~\$450 peak revenue potential
- Proven US commercial infrastructure:** Dedicated Sale force focused on PCPs & Women's health supported by strong HCP and consumer marketing, demonstrated payor success, established distribution networks
- Regulatory success** with FDA, EMA, Health Canada, and others
- Poised to turn **cash flow positive** by end of 2025



Established US commercial infrastructure

Dedicated Field Sales Team

80 sales reps with 1 product in the bag

Focus on PCP and Women's Health

Complemented by digital marketing programs

Shield and Viatris Co-Commercial partnership

Demonstrated Payor Success

Broad Medicaid coverage across the nation

Coverage by 3 of the 4 largest PBMs

Successful PA management

Established patient assistance

Established Distribution Networks

3PL logistics in place

Specialty pharmacy relationships

Distribution licenses in all 50 states

Proven BI and data analytics capabilities

Partnership opportunities

In License

Actively seeking products that can leverage our US infrastructure and expand our portfolio

Ideal product profile is highly synergistic with ACCRUF_eR®

- FDA approved and/or approved outside US
- Ready for commercialization in US
- Late-stage Phase 3 asset

Product poised to address a clear unmet need in the market with potential for label expansion in the future

Out License

Focused on ensuring ACCRUF_eR® is accessible to as many people globally living with iron deficiency anemia as possible

Seeking collaborators and global partners with extensive local market knowledge and highly experienced teams

Regions actively pursuing partners: MENA/GCC; LATAM; Asia Pac

To discuss potential partnership opportunities: partnerships@shieldtx.com
We are open to flexible deal structures, enabling faster alignment and smoother negotiations.



Thank You!

David Childs – VP Strategic Alliances

www.shieldtherapeutics.com

